Engineering of pharmaceutical materials: An industrial perspective

Journal of Pharmaceutical Sciences

Volumn 97, Issue 8, 2008, Pages 2855-2877

  Chow, Kwok ^a   Tong, Henry H Y ^b   Lum, Susan ^a   Chow, Albert H L ^c  

^a Patheon Inc   (Canada)

^b MACAO POLYTECHNIC INSTITUTE   (Macao)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Crystal engineering; Crystallization; Formulation; Particle size; Pharmaceutical manufacturing; Polymorphism; Preformulation; Selection of salt forms

Indexed keywords

ATORVASTATIN; EXCIPIENT; INDINAVIR; LACTOSE; MICROCRYSTALLINE CELLULOSE; NIFEDIPINE; PARACETAMOL; PAROXETINE; RITONAVIR;

COMPUTER SIMULATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG STABILITY; ENGINEERING; GLASS TRANSITION TEMPERATURE; PARTICLE SIZE; REVIEW; X RAY DIFFRACTION;

EID: 52449119950     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21212     Document Type: Review

References (186)

1. Schmidt GMJ. 1967. The photochemistry of the solid state. In Reactivity of the photoexcited organic molecule. Proceedings of the Thirteenth Conference on Chemistry at the University of Brussels, October 1965. Interscience Belfast 227-288.
2. Schmidt GMJ. 1971. Photodimerization in the solid state. Pure Appl Chem 27:647-678.
3. Desiraju GR. 1989. Crystal engineering: The design of organic solids. Amsterdam: Elsevier. pp. 1-25.
4. Braga D, Grepioni F. 1999. Crystal engineering: From molecules and crystals to materials in crystal engineering. In: Braga D, Grepioni F, Orpen AG, editors. Crystal engineering: From Molecules and crystals to materials. Netherlands: Kuuwer Academic Publishers pp. 421-441.
5. Chan H, Grant David JW. 1989. Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. Int J Pharm 57:117-124.
6. Patience DB. 2002. Crystal engineering through particle size and shape monitoring, modeling, and control. Ph.D. Dissertation (Chemical Engineering) University of Wisconsin-Madison.
7. Ulrich J, Jones MJ. 2004. Industrial crystallization: Developments in research and technology. Chem Eng Res Des 82:1567-1570.
8. Braga D, D'Addario D, Maini L, Polito M, Giaffreda S, Rubini K, Grepioni F. 2006. Applications of crystal engineering strategies in solvent-free reactions: Towards a supramolecular green chemistry. In: Tiekink ERT, Vittal JJ, editors. In frontiers in crystal engineering. West Sussex: Wiley. pp. 1-23.
9. Davey RJ, Allen K, Blagden N, Cross WI, Lieberman HF, Quayle MJ, Righini S, Seton L, Tidy GT. 2002. Crystal engineering - Nucleation, the key step. Cryst Eng Comm 4:257-264.
10. Braga D, Brammer L, Champness NR. 2005. New trends in crystal engineering. Cryst Eng Comm 7:1-19.
11. Brittain HG. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
12. Rodriguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodriguez-Hornedo N. 2004. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Adv Drug Deliv Rev 56:241-274.
13. Vippagunta S, Brittain HG, Grant DJW. 2001. Crystalline solids. Adv Drug Deliv Rev 48:3-26.
14. Hilfiker R. 2005. Polymorphism in the pharmaceutical industry. Basel: Wiley-VCH.
15. Singhal D, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56:335-347.
16. Blagden N, Davey RJ. 2003. Polymorph selection: Challenges for the future? Crystal Growth Des 3: 873-885.
17. Winn D, Doherty MF. 2000. Modeling crystal shapes of organic materials grown from solution. AIChE J 46:1348-1367.
18. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. 2002. Fundamental effects of particle morphology on lung delivery: Prediction of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 19:239-245.
19. Crowder TM, Hickey AJ, Louey MD, Orr N. 2003. A guide to pharmaceutical particulate sciences. Boca Raton: Interpharm/CRC. pp 155-200.
20. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
21. Hilden LR, Morris KR. 2004. Physics of amorphous solids. J Pharm Sci 93:3-12.
22. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 21:133-193.
23. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-11.
24. Khankari RK, Grant DJW. 1995. Pharmaceutical hydrates. Thermochim Acta 248:61-79.
25. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. 2006. Pharmaceutical co-crystals. J Pharm Sci 95:499-516.
26. Bastin RJ, Bowker MJ, Slater BJ. 2000. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org Process Res Dev 4:427-435.
27. Stahl PH, Wermuth CG. 2002. Handbook of pharmaceutical salts. Properties, selection and use. Zurich: Verlag Helvetica Chimica Acta.
28. Yu L, Reutzel-Edens S, Mitchell CA. 2000. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies. Org Pro Res Dev 4:396-402.
29. Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson Ö. 2003. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci 100:2180-2184.
30. Swaminathan V, Kildsig DO. 2002. Polydisperse powder mixtures: Effect of particle size and shape on mixture stability. Drug Dev Ind Pharm 28:41-48.
31. Rasenack N, Muller BW. 2002. Crystal habit and tableting behavior. Int J Pharm 244: 45-57.
32. Chikhalia V, Forbes RT, Storey RA, Tichurst M. 2006. The effect of crystal morphology and mill type on milling induced disorder. Eur J Pharm Sci 27:19-26.
33. York P. 1978. Particle slippage and rearrangement during compression of pharmaceutical powders. J Pharm Pharmacol 30:6-10.
34. Sun C, Grant DJW. 2001. Influence of crystal shape on the tableting performance of 1-lysine monohydrochloride dehydrate. J Pharm Sci 90: 569-579.
35. Alderborn G, Nystrom C. 1982. Studies in direct compression of tablet III. The effect on tablet strength of changes in particle shape and texture obtained by milling. Acta Pharmceutica Suecica 19:147-157.
36. Alpar O, Heesey JA, Shotton E. 1970. The compression properties of lactose. J Pharm Pharmac 22:1S-7S.
37. Bandyopadhyay R, Grand DJW. 2002. Plasticity and slip system of plate-shaped crystals of L-lysine monohydrochloride dehydrate. Pharm Res 19: 491-496.
38. Nakagawa H. 1982. Effects of tableting procedures on the preferred orientation of crystalline particles. Chem Pharm Bull 30:1401-1407.
39. Shotton E, Obiorah BA. 1973. The effect of particle shape and crystal habit on properties of sodium chloride. J Pharm Pharmac 25:37P-43P.
40. Burt HM, Mitchell AG. 1979. Dissolution anisotropy in nickel sulfate alph-hexahydrate crystals. Int J Pharm 3:261-274.
41. Burt HM, Mitchell AG. 1980. Effect of habit modification on dissolution rate. Int J Pharm 5:239-251.
42. Boldyreva EV. 2003. High-pressure-induced structural changes in molecular crystals preserving the space group symmetry: Anisotropic distortion/ isosymmetric polymorphism. Cryst Eng 6:235-254.
43. Sands DE. 1969. Introduction to crystallography. New York: W.A. Benjamin. pp. 66-67.
44. Hartman P. 1963. Crystal form and crystal structure. In: Fox D, Labes MM, Weissberger A, editors. Physics and chemistry of organic solid state. Vol. I. New York: Wiley Interscience. Chapter 6, pp. 369-409.
45. Price SL. 2004. The computational prediction of pharmaceutical crystal structures and polymorphism. Adv Drug Deliv Rev 56:301-319.
46. Bernstein J. 2004. Crystal Structure Prediction and Polymorphism. Proceedings from the Symposium Crystal in Supramolecular Chemistry. ACA Trans 39:14-23.
47. Day GM, Chisholm J, Shan N, Motherwell WDS, Jones W. 2004. An assessment of lattice energy minimization for the prediction of molecular organic crystal structures. Crystal Growth Des 4:1327-1340.
48. Day GM, Motherwell WDS, Ammon HL, Boerrigter SXM, Della Valle RG, Venuti E, Dzyabchenko A, Dunitz JD, Schweizer B, Van Eijck BP, Erk P, Facelli JC, Bazterra VE, Ferraro MB, Hofmann DWM, Leusen FJJ, Liang C, Pantelides CC, Karamertzanis PG, Price SL, Lewis TC, Norwell H, Torrisi A, Scheraga HA, Arnautova YA, Schmidt MU, Verwer P. 2005. A third blind test of crystal structure prediction. Acta Crystallogr B61:511-527.
49. Clydesdale G, Roberts K, Telfer G, Grant DJW. 1997. Modeling the crystal morphology of α-lactose monohydrate. J Pharm Sci 86:135-141.
50. Day GM, Price SL, Leslie M. 2001. Elastic constant calculations for molecular organic crystals. Crystal Growth Des 1:13-27.
51. Coombes DS, Clatlow RA, Gale JD, Hardy MJ, Saunders MR. 2002. Theoretical and experimental investigations on the morphology of pharmaceutical crystals. J Pharm Sci 91:1652-1659.
52. Gould PL. 1986. Salt selection for basic drugs. Int J Pharm 33:201-217.
53. Gardner CR, Walsh CT, Almarsson Ö. 2004. Drugs as materials: Valuing physical form in drug discovery. Nature Rev Drug Discov 3:926-934.
54. Almarsson Ö, Zaworotko M. 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? ChemInform 35:1889-1896.
55. Almarsson Ö, Hickey M, Peterson M, Morissette S, Soukasene S, McNulty C, Tawa M, McPhee JM, Remenar JF. 2003. High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Crystal Growth Des 3: 927-933.
56. Huang L, Tong W. 2004. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 56:321-334.
57. Balbach S, Korn C. 2004. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm 275:1-12.
58. Benson RS, MacCabe DJ. 2004. From good manufacturing practice to good manufacturing performance. Pharm Eng July/August: 26-34.
59. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim Acta 2:259-271.
60. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. II. Theory of thermodynamic rules. Mikrochim Acta 2:273-316.
61. Grant DJW, Higuchi T. 1990. Solubility behavior of organic compounds: Techniques of chemistry. Vol. XXI, New York: Wiley. pp. 32-46.
62. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. 1995. Pharmaceutical solids: A strategic approach to regulatory considerations. Pharm Res 12:945-954.
63. Raw AS, Furness MS, Gill DS, Adams RC, Holcombe FO Jr, Yu LX. 2004. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAS). Adv Drug Discov Rev 56:397-414.
64. International Conference on Harmonisation. Harmonised Tripartite Guideline. Specifications: Test procedures and acceptance criteria for drug substances and new drug products: Chemical stances 1999 (ICH Q6A).
65. Morris KR, Gtiesser UJ, Eckhardt CJ, Stowell JG. 2001. Theoretical approaches to physical transformation of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91-114.
66. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25.
67. Sun C, Grant DJW. 2001. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res 18:274-280.
68. Trask AV, Shan N, Motherwell WDS, Jones W, Feng S, Tan RBH, Carpenter KJ. 2005. Selective polymorph transformation vis solvent-drop grinding. Chem Commun (Camb) 21:880-882.
69. Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. 2007. Celecoxib:nicotimide dissociation: Using excipients to capture the cocrystals's potential. Mol Pharm 4:386-400.
70. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzman HR, Almarsson ö. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 125:6456-6457.
71. Brader ML, Sukumar M, Pekar AH, McClellan DS, Chance RE, Flora DB, Cox AL, Irwin L, Myers SR. 2002. Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol 20:800-804.
72. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral Bioavailability of a low solubility API. Pharm Res 23:1888-1897.
73. Kitaigorodsky AI. 1973. Molecular crystals and molecules. New York: Academic Press. pp. 94-133.
74. Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson Ö. 2003. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci 100:2180-2184.
75. Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR. 2005. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubility. Cryst Growth Des 5:2299-2309.
76. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids, molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 126:13335-13342.
77. Haynes DA, Jones W, Motherwell WDS. 2005. Occurrence of pharmaceutically acceptable anions and cations in the CSD. J Pharm Sci 94:2111-2120.
78. Bond A, Jones W. 2002. Controlling crystal architecture in molecular solids: The supermolecular approach. In: Jones W, Rao NR, editors. Supramolecular organization and materials design. Cambridge: Cambridge University Press. pp. 391-443.
79. Jayasankar A, Somwangthanaroj A, Shao ZJ, Rodríguez-Hornedo N. 2006. Cocrystal formation during cogrinding and storage is mediated by amorphous phase. Pharm Res 23:2381-2392.
80. Rodríguez-Hornedo N, Nehm SJ, Seefledt KF, Pagan-Torres Y, Falkiewicz CJ. 2006. Reaction crystallization of pharmaceutical molecular complex. Mol Pharm 3:362-367.
81. Morris KR. 1999. Structural aspects of hydrates and solvates. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker. pp. 125-181.
82. Shefter E, Higuchi T. 1963. Dissolution behavior of crystalline solvates and nonsolvated forms of some pharmaceuticals. J Pharm Sci 25:37P-13P.
83. Finckenor LE. 1980. Beclomethasone dipropio-nate-hexane and aerosol prepared there from. US patent 4225597.
84. Jinks PA. 1989. Physically modified beclomethasone dipropionate suitable for use in aerosol. US patent no. 4810488.
85. Neale PJ, Taylor AJ. 1998. Aerosol formulations beclomethasone dipropionate-1, 1,1, 2-tetrafluoroethane solvate US patent no 5833950.
86. Swaminahan V, Kildsig DO. 2001. An Examination of the moisture sorption characteristics of commercial magnesium stearate. AAPS Pharm Sci Tech 2:28.
87. Katrusiak A, Katrusiak A. 2004. Thyroxine Revisited. Int J Pharm 93:3066-3075.
88. Chow K. 1989. Crystal modification of griseofulvin using interacting solvents, n-alkanoic acids. PhD thesis. University of Toronto.
89. Gohel MC. 2005. A review of co-processed direct compressible excipients. J Pharm Pharmaceut Sci (www.cspscanada.org) 8:76-93.
90. McManus J, Anousis N, Genus JF, Hancock C. 2003. Latonization process. US patent no. 6525205.
91. Hancock BC. 2001. Disordered drug delivery: Destiny, dynamics and the Deborah number, The 138th British Pharmaceutical Conference, Glasgow, 23th-26th September (2001).
92. Fu Y, Yang S, Jeong SH, Kimura S, Park K. 2004. Oral fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 21:433-475.
93. Hancock BC, Shamblin SL, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 12:799-806.
94. Mao C, Chamarthy SP, Byrn SR, Pinal R. 2006. A calorimetric method to estimate molecular mobility of amorphous solids. Pharm Res 23:2269-2276.
95. Vyazovkin S, Dranca I. 2006. Probing beta relaxation in pharmaceutically relevant glasses by using DSC. Pharm Res 23:422-428.
96. Bhugra C, Shmeis R, Krill SL, Pikal MJ. 2006. Prediction of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition and temperatures below the glass transition. Pharm Res 23:2277-2290.
97. Tombari E, Presto S, Johari GP, Shanker RM. 2006. Dynamic heat capacity and relaxation time of ultraviscous melt and glassy acetaminophen. J Pharm Sci 95:1006-1021.
98. Liu J, Rigsbee DR, Stotz C, Pikal MJ. 2002. Dynamics of pharmaceutical amorphous solids: The study of enthalpy relaxation by isothermal microcaloritmetry. J Pharm Sci 91:1853-1862.
99. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872.
100. Zhou D, Grant DJW, Zhang GGZ, Schmitt EA. 2007. A calorimetric investigation of thermodynamic and molecular contributions to the physical stability of two pharmaceutical glasses. J Pharm Sci 96:71-83.
101. Aso Y, Yoshioka S, Kojima S. 2004. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J Pharm Sci 93:384-391.
102. Gunawan L, Johari GP, Shanker RM. 2006. Structural relaxation of acetaminophen glass. Pharm Res 23:967-979.
103. Aso Y, Yoshioka S, Kojima S. 2000. Relationship between the crystallization rates of amorphous nifidipine, phenobarbital and flopropione and their molecular mobility as measured by their enthalpy relaxation and H1 NMR relaxation times. J Pharm Sci 89:408-416.
104. Hancock BC, Dalton CR, Pikal MJ, Shamblin SL. 1998. A pragmatic test of a simple calorimetric method for determining the fragility of some amorphous pharmaceutical materials. Pharm Res 15: 762-767.
105. Ramos JJM, Pinto SS, Diogo HP. 2005. Molecular mobility in raffinose in the crystalline pentahydrate form and in the amorphous anhydrate form. Pharm Res 22:1142-1148.
106. Correia NT, Ramos JJM, Descamps M, Collins G. 2001. Molecular mobility and fragility in indomethcin: A thermally stimulated depolarization current study. Pharm Res 18:1767-1774.
107. Amidon G, Lennernäs H, Shah V, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in Vivo Bioavailability. Pharm Res 12:413-420.
108. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
109. Van Drooge DJ, Henrichs WLJ, Frijlink HW. 2004. Anomalous dissolution behaviour of tablets prepared from sugar-based solid dispersions. J Control Release 97:441-452.
110. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. 1999. Forecasting the in vivo performance of four low solubility drugs the in vitro dissolution data. Pharm Res 16:1876-1882.
111. FDA document: Pfizer Citizen Petition on Amorphous Lipitor (Docket #2005P-0452).
112. Tessler L, Aronhime J, Lifshitz-Liron R, Maidan-Hanoch D, Hasson N. 2005. Processes for preparing amorphous atorvastatin hemi-calcium. US patent 7189861.
113. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
114. Vandecruys RP, Gerebern P, De Conde VFV, Gilis PMV, Peeters J. 1998. Pellets having a core coated with an antifungal and a polymer. PCT patent PCT/EP98/01773.
115. Shanker RM. 2006. Formulation of solid dispersions to retard kinetics of precipitation of structurally diverse, poorly water soluble compounds. AAPS Conference.
116. Tanno F, Nishiyama Y, Kokubo H, Obara S. 2004. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm 30:9-17.
117. Curatolo WJ, Nightingale JAS, Shanker RM, Sutton SC. 2000. Basic drug compositions with enhanced bioavailability. US Patent 6548555.
118. Turnbull D, Fisher JC. 1949. Rate of nucleation in condensed systems. J Chem Phys 17:71-73 and 429.
119. Saleki-Gerhardt A, Zografi G. 1994. Non-isothermal and isothermal crystallization of sucrose from the amorphous state. Pharma Res 11:1166-1173.
120. Nyamweya N, Hoag SW. 2000. Assessment of polymer-polymer interactions in blends of HPMC and film forming polymers by modulated temperature differential scanning calorimetry. Pharm Res 17:625-631.
121. Tajber L, Corrigan OI, Healy AM. 2005. Physicochemical evaluation of PVP-thiazide diuretic interactions in co-spray-dried composites-analysis of glass transition composition relationships. Eur J Pharm Sci 24:553-563.
122. Shalaev EY, Lu Q, Shalaeva M, Zografi G. 2000. Acid-catalyzed inversion of sucrose in the amorphous state at very low levels of residual water. Pharm Res 17:366-370.
123. Telang C, Yu L, Suryanarayanan R. 2003. Effective inhibition of mannitol crystallization in frozen solutions by sodium chloride. Pharm Res 20:660-667.
124. Suihko EJ, Forbes RT, Apperley DC. 2005. A solid-state NMR study of molecular mobility and phase separation I co-spray-dried protein-sugar particles. Eur J Pharm Sci 25:105-112.
125. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinypyrrolidone) and polycvinylpyrroli- done-co-vinyl-acetate) in relations to indomethacin crystallization. Pharm Res 16:1722-1728.
126. Vasanthavada M, Tong W, Joshi Y, Kislalioglu MS. 2005. Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
127. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23:2417-2426.
128. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
129. Karanth H, Shenoy VS, Murthy RR. 2006. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS Pharm Sci Tech 7: Article 87.
130. Buckton G, Darcy P. 1995. The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders. Int J Pharm 123:265-271.
131. DMV Excipient Guide. 2005. Directly compressible lactose: General considerations. The Netherlands: DMV International.
132. Zhang GGZ, Law D, Schmitt EA, Schmitt EA, Qiu Y. 2004. Phase transformation considerations during process development and manufacture of solid dosage forms. Adv Drug Deliv Rev 56:371-390.
133. Sprockel OL, Lai C, Wei C, Kothari SH, Discordia RP, Kim S. 2004. Pharmaceutical tablet having a high API content. US Patent no. 20040208924 - Bristol Meyer's patent - Good reference on milling on compaction.
134. Heng JYY, Thielmann F, Williams DR. 2006. The effect of milling on the surface properties of form I paracetamol crystals. Pharm Res 23:1919-1927.
135. Brodka-Pfeiffer K, Langguth P, Graß P, Häusler H. 1985. Influence of mechanical activation on the physical stability of salbutamol sulfate. Eur J Pharm Biopharm 56:393-400.
136. Otsuka M, Otsuka K, KaneniwaA N. 1994. Relation between polymorphic transformation pathway during grinding and the physical chemical properties of bulk powders for pharmaceutical preparations. Drug Dev Ind Pharm 20:1649-1660.
137. Müller RH, Jacobs C. 2002. Buparvaquone mucoadhesive nanosuspension: Preparation, optimism and long-term stability. Int J Pharm 237: 151-161.
138. Sayani AP, Maleki M, Chow KY. 2004. Pharmaceutical compositions. PCT patent no WO2004/091280.
139. Wennerstrum S, Kendrick T, Tomaka J, Cain J. 2002. Size reduction solutions for hard-to-reduce materials. Powder Bulk Eng January: 1-5.
140. FDA . 1999. Guidance for industry. SUPAC-IR/MR: Immediate release and modified release solid oral dosage forms, manufacturing equipment addendum. U.S. Department of Heath and Human Services, Food and Drug Administration, Center of Drug Evaluation and Research (CDER).
141. Byard SJ, Jackson SL, Smail A, Bauer M, Apperley DC. 2005. Studies on the crystallinity of a pharmaceutical development drug substance. J Pharm Sci 94:1321-1335.
142. Stephenson GA, Forbes RA, Reutzel-Edens SM. 2001. Characterization of the solid state: Quantitative issues. Adv Drug Deliv Rev 48:67-90.
143. Briggner LE, Buckton G, Bystrom K, Darcy P. 1994. The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders. Int J Pharm 105: 125-135.
144. Tong HHY, Shekunov BY, York P, Chow AHL. 2002. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 19:640-648.
145. Tong HHY, Shekunov BY, York P, Chow AHL. 2005. Surface characterization of salmeterol xinafoate powders by inverse gas chromatography at finite coverage. J Pharm Sci 94:695-700.
146. Ohta M, Buckton G. 2004. Determination of the changes in surface energetics of cefditoren pivoxil as a consequence of processing induced disorder and equilibration to different relative humidities. Int J Pharm 269:81-88.
147. Ward S, Perkins M, Zhang J, Roberts CJ, Madden CE, Luk SY, Patel N, Ebbens SJ. 2005. Identifying and mapping surface amorphous domains. Pharm Res 22:1195-1202.
148. Zhang J, Ebbens S, Chen X, Jin Z, Luk S, Madden C, Patel N, Roberts J. 2006. Determination of surface free energy of crystalline and amorphous lactose by atomic force microscopy adhesion measurement. Pharm Res 23:401-407.
149. Böhm BHL, Müller RH. 1999. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. PSTT 2:229-336.
150. Müller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy - Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19.
151. Bosch HW, Cooper ER. 2001. Bioadhesive nanoparticulate compositions having cationic surface stabilizers. PCT Patent no. WO 01/26635.
152. Dearn AR. 2000. Atovaquone pharmaceutical compositions. U.S. Patent no. 6018080.
153. Dearn AR. 2003. Atovaquone pharmaceutical compositions. U.S. Patent no. 6649659.
154. Shekunov Y, Chattopadhyay P, Seitzinger J, Huff R. 2006. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 23:397-404.
155. Date AA, Patravale VB. 2004. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interface Sci 9:222-235.
156. Marchisio DL, Rivautella L, Barresi AA. 2006. Design and scale-up of chemical reactors for nanoparticle precipitation. AlChe J 52:1877-1887.
157. Müller RH, Möschwitzer J, Bushrab FN. 2006. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta RB, Kompella UB, editors. Nanoparticle technology for drug delivery. NY: Taylor & Francis. pp. 21-52.
158. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. 1992. Surface modified drug nanoparticles. U.S. patent no. 5145684.
159. Kupperblatt G, Huang J, Ong K, Saghir S, Tan R, Wilson D, Rogers T, Fransen K. 2004. Evaluation of the processability and bioavailability of solubility-enhanced powder. AAPS Journal 6:T2185.
160. Paul EL, Tung HH, Midler M. 2005. Organic crystallization processes. Powder Tech 159:133-143.
161. Mohan R, Myerson AS. 2002. Growth kinetics: A thermodynamic approach. Chem Eng Sci 57:4277-4285.
162. Braatz RD. 2002. Advanced control of crystallization processes. Annu Rev Control 26:87-99.
163. Kim S, Wei C, Kiang S. 2003. Crystallization process development of an active pharmaceutical ingredient and particle engineering via the use of ultrasonics and temperature cycling. Org Proc Res Dev 7:997-1001.
164. Midler M Jr, Paul EL, Whittington EF, Futran M, Liu PD, Hsu J, Pan SH. 1991. Crystallization method to improve crystal structure and size. US patent no. 5,314,506.
165. Roberts KJ. 2006. Recent applications of in-process analytical techniques to monitoring & controlling the final product form of organic specialty chemicals. Oxford: Presentation at the Advances in Process Analytics & Control Technology. (APACT).
166. Shekunov BY, York P. 2000. Crystallization processes in pharmaceutical technology and drug delivery design. J Crystal Growth 211:122-136.
167. Szabó-Révész P, Hasznos-Nezdei M, Farkas B, Göcz H, Pintye-Hódi K, Erös I. 2002. Crystal growth of drug materials by spherical crystallization. J Crystal Growth 237-239. 2240-2245.
168. Blandin AF, Mangin D, Rivoire A, Klein JP, Bossoutrot JM. 2003. Agglomeration in suspension of salicyclic acid fine particles: Influence of some process parameters on kinetics and agglomerate final size. Powder Tech 130:316-323.
169. Yu LX, Lionberger RA, Raw AS, D'Costa R, Wu H, Hussain AS. 2004. Applications of process analytical technology to crystallization processes. Adv Drug Del Rev 56:349-369.
170. Birch M, Fussell SJ, Higginson PD, McDowall N, Marzanio I. 2005. Towards a PAT-based strategy for crystallization development. Org Process Res Dev 9:360-364.
171. Fujiwara M, Nagy ZK, Chew JW, Braatz RD. 2005. First-principles and direct design approaches for the control of pharmaceutical crystallization. J Process Control 15:493-504.
172. Braatz RD. 2002. Advanced control of crystallization processes. Annu Rev Control 26:87-99.
173. Grön H, Borissova A, Roberts KJ. 2003. In-process ATR-FTIR spectroscopy for closed loop supersaturation control of a batch crystallizer producing monosodium glutamate crystals of defined size. Ind Eng Chem Res 42:198-206.
174. Togkalidou T, Tung HH, Sun Y, Andrews A, Braatz RD. 2002. Solution concentration prediction for pharmaceutical crystallization processes using robust chemometrics and ATR FTIR spectroscopy. Org Proc Res Dev 6:317-322.
175. Calderon De Anda J, Wang XZ, Roberts KJ. 2005. Multi-scale segmentation image analysis for the in-process monitoring of particle shape with batch crystallisers. Chem Eng Sci 60:1053-1065.
176. Calderon De Anda J, Wang XZ, Lai X, Roberts KJ. 2005. Classifying organic crystals via in-process image analysis and the use of monitoring charts to follow polymorphic and morphological changes. J Process Control 15:785-797.
177. Nilsen CN, Fabian S, Grimm J, Liu F, Manzo S, Sorgi K. 2006. API crystal engineering in early development. Presentation at the AIChE annual conference 2006.
178. Zhou GX, Fujiwara M, Woo XY, Rusli E, Tung HH, Starbuck C, Davidson O, Ge Z, Braatz RD. 2006. Direct design of pharmaceutical antisolvent crystallization through concentration control. Crystal Growth Des 6:892-898.
179. Threlfall T. 2000. Crystallization of polymorhs: Thermodynamic insight into the role of solvent. Org Pro Res Dev 4:384-390.
180. Beckmann W. 2003. Crystallization of pharmaceutical compounds polymorphs, Pseudo-polymorphs and particle formation. Eng Life Sci 3:113-120.
181. Agarwal P, Berglund KA. 2003. In situ monitoring of calcium carbonate polymorphs during batch crystallization in the presence of polymeric additives using Raman spectroscopy. Crystal Growth Des 3:941-946.
182. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 119:1767-1772.
183. Capes JS, Cameron RE. 2007. Effect of polymer addition on the contact line crystallisation of Paracetamol. Cryst Eng Comm 9:84-90.
184. Chen S, XL H, Yu L. 2005. Cross nucleation between ROY polymorphs. J Am Chem Soc 127:17439-17444.
185. Mirmehrabi M, Rohani S. 2005. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci 94:1560-1576.
186. FDA. 2004. Challenge and opportunity on the critical path to new medical products. U.S. Department of Heath and Services, Food and Drug Administration.